NSE: MOLDTKPAC · BSE: 533080 · ISIN INE893J01029
Mold-Tek Packaging Limited stock analysis
Mold-Tek Packaging Limited ranks #1927 in the TickerSutra evidence-ranked universe with a score of 50/100 and 95% data confidence. The latest captured fundamentals show ROCE of 13.3%, quarterly sales growth of 24.9% and quarterly profit growth of 17.4%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- CWIP indicates an active capacity pipeline
Risks and constraints
- No calculated threshold risk in the current snapshot.
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹631cr | ₹121cr | ₹64cr | 19.0% |
| 2023 | ₹730cr | ₹136cr | ₹80cr | 19.0% |
| 2024 | ₹699cr | ₹133cr | ₹67cr | 19.0% |
| 2025 | ₹781cr | ₹142cr | ₹61cr | 18.0% |
| 2026 | ₹887cr | ₹173cr | ₹73cr | 19.0% |
| TTM | ₹947cr | ₹181cr | ₹76cr | 19.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Mold-Tek Packaging Limited has informed the Exchange that Record date for the purpose of Bonus is 09-Oct-2026.
Positive CatalystMold-Tek Packaging Ltd - 533080 - Corporate Action-Fixes Record Date For Bonus Issue Of Equity SharesBSE · 28 Sept 2026Intimation of Record date for Bonus Issue of Equity Shares
RoutineShareholders meetingNSE · 23 Sept 2026Mold-Tek Packaging Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 21, 2026. Further, the company has informed the Exchange regarding voting results.
RoutineMold-Tek Packaging Ltd - 533080 - Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportBSE · 23 Sept 2026Voting Results and Scrutinizer''s Report
RoutineShareholders meetingNSE · 21 Sept 2026Mold-Tek Packaging Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 21, 2026
MANAGEMENT COMMENTARY
Signals from filed documents
• Lower MOQs enable newer SKUs and smaller brands to enter the portfolio, with several launches already secured. • New capacity in Panipat strengthens Mold-Tek's presence in the North, a major agro and FMCG belt. PHARMA • Successfully completed 25+ plus audits with regulatory pharma firms and continuous orders with major share from Laurus Labs, Graviti, MSN, Marksans, Ajanta, Inventia Pharma.
Our revenue increased by 13.48%, supported by an 11.41% growth in sales volume. EBITDA increased by 20.71%, reflecting improved operating leverage, better profitability and greater operational efficiency. Net profit grew by 20.35%, demonstrating the Company's ability to translate healthy volume growth into stronger earnings.
Bhargav Buddhadev: Congratulations on a good set of numbers. Sir, my first question is that is it fair to say that we would have seen some volume decline. Obviously, because of elevated RM prices, there might be de-stocking.
Lakshman Rao: It should at least remain at 10% to 15% range. We are confident this time paint will grow in double-digit and the signs so far are good. But for at least the war stops in a couple of months' time, hopefully, we'll be seeing even 15% growth is possible because of very handsome growth in Asian paint sale for us.
I'm glad to inform you that we have made a historical quarter. The turnover crossed INR300 crores, partially helped by increased raw material costs. However, one of the most important points here is the per kg EBITDA has shot up to INR46.7 per kg, which is historically around INR40, INR42 was the best in the last several years.
He has played a vital role particularly in Company’s Pharma Packaging segment and has led several innovative projects. He played a key role in facilitating and executing the Memorandum of Understanding with Vibe Generation Holdings, a UK-based technology and marketing company, which is intended to support the Company’s efforts in technology, increasing product diversification and developing opportunities in domestic
0.85% of Total Income) is spent for total R&D and 100% of the same is attributable towards improvement of the environmental and social impacts of product and processes b. Technology absorption: The Company operates in a technology-intensive industry where continuous innovation is essential to maintain market leadership. Mold-Tek has a centralized integrated tool room that plays a pivotal role in: • Mold development a
This reduces human error in quality evaluation. NEW SHAPES & BUSINESS STREAMS OPERATIONAL EFFICIENCY Annual Report 2026 | 3 Our Core Cometencies Our Clientele Innovation as per market needs Operational Excellence Market Leader in Rigid Plastic Packaging Pioneers in the field of In-Mould Labelling (IML) in India Diversified Geographic Presence 100% Backward Integration World-class Research & Development 4 | Annual Rep
• New capacity in Panipat strengthens Mold-Tek's presence in the North, a major agro and FMCG belt. PHARMA • Successfully completed 25+ plus audits with regulatory pharma firms and continuous orders with major share from Laurus Labs, Graviti, MSN, Marksans, Ajanta, Inventia Pharma. • First commercial orders executed for new SKUs like 28mm CRC & 53mm CRC for couple of customers.
The Board recommends the Special Resolution set out at Item No.8 of the Notice for the approval by the members. 9 and 10 The Board of Directors of the Company, at its meeting held on August 26, 2026, considered and approved, subject to the approval of the Members and such statutory and regulatory approvals as may be applicable, the proposal for issue of bonus equity shares in the ratio of 1 (One) bonus equity share o
The transcript and audio recording of the earnings call is also uploaded on the Company’s website as well as filed with the stock exchanges where the securities of the Company are listed. Presentations made to institutional investors and financial analysts on the financial results are filed with the stock exchanges and uploaded on the Company’s website. Mold-Tek Packaging Limited 128 | Annual Report 2026 • Website: Y
Because this is the entire pass on cost, right? If we are passing -- if there is price increase in raw material is about INR30 from INR100 to INR130, and we are selling at INR150. It's INR180 to -- increase from INR150 to INR180 due to which by eyes, we look that the margins are down.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…